Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc.’s anticipated launch of its immunotherapy candidate, cretostimogene grenadenorepvec, as a potential bladder-sparing treatment in 2026 project sales growth to approximately $2.6 billion by 2034, indicating a favorable long-term financial outlook. The expected differentiation in efficacy and durability from BOND-003’s data signals a strong potential for regulatory approval, bolstering confidence in the company’s market positioning and its ability to address unmet patient needs in the NMIBC space. Additionally, the capabilities of CG Oncology regarding manufacturing and commercial readiness stand to enhance investor reassurance and firm up its competitive stance against key players like Inlexzo.

Bears say

CG Oncology faces significant risks regarding its commercialization prospects, highlighted by the potential for negative trial outcomes and slower-than-expected trial enrollment, which may hinder market entry and reduce the overall market potential for its therapies. The company's reliance on successful reimbursement from payers could be jeopardized if real-world adherence and durability of treatment outcomes are not demonstrated, especially considering the substantial upfront investment costs associated with its candidate therapies. Furthermore, the possibility of third-party challenges or lapses in intellectual property protection raises additional concerns about CG Oncology's competitive positioning in the biopharmaceutical market.

CGON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 11 analysts, CGON has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.